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A major component of the population of people who have epilepsy are people with a learning disability. As a group, such 
individuals often have complex epilepsy which is refractory to treatment. Current available measures to assess the outcomes 
of therapeutic interventions in epilepsy are based on seizure frequency, seizure severity and quality-of-life measures, but 
have not been validated in people with a learning disability. Thus, we do not know if such measures of outcome serve the 
needs of this group. This review examines how able we are to assess the efficacy of our interventions to control epilepsy 
in people with learning disability. It is suggested that a standard data set is necessary as the basis of the assessment of any 
therapeutic intervention. Central components of this data set would encompass a definition of important characteristics of 
an individual, a description of their epilepsy and an assessment of the impact of their condition on both their own and their 
carer’s health. The approach to obtaining this information should employ a methodology which can allow for environmental 
influences. 
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INTRODUCTION 
As a result of complex associations with social 
stigma, psychological distress and physical morbid- 
ity, epilepsy and its manifestations demand the high- 
est quality of care from a broad range of health, and 
other, professionals’. Assessing the quality of care 
and, more specifically, the outcomes of care interven- 
tions has become a major focus for all health services, 
and epilepsy services are no different. Central to this 
drive in the UK is the Cochrane collaboration, or clin- 
ical effectiveness campaign, which aims to encourage 
health services and practitioners to use interventions 
which are of proven efficacy. Epilepsy management 
and, in particular, pharmacological interventions have 
largely been assessed within the criteria of clinical ef- 
fectiveness. The double-blind randomized controlled 
trial, the gold standard in the Cochrane approach, is 
now the norm for new phannacotherapies, particu- 
larly when comparing these with more established 
treatments. 
Outcomes used in these trials are normally: 
(1) seizure, (2) drop out and (3) side-effect frequency. 
1059-1311/97/050331 + 06 $12.00/O 
Increasingly, broader social outcomes are accepted 
through a range of quality-of-life measures. The va- 
lidity of these measures in the population of people 
with learning disability is not established*. 
People with learning disability are a major compo- 
nent of the population of people with epilepsy who 
receive specialist care3, yet they do not fit well into 
these established evaluation processes. This can be 
seen by the paucity of randomized controlled trials- 
with a continued trend to open trials and retrospective 
case-note evaluations. 
It may be that the complexity of study design 
in a population with this range of additional needs, 
namely: (1) communication difficulties, (2) increased 
morbidities such as epilepsy and behavioural disor- 
ders and (3) increased care needs for activities of 
daily living, has hindered the development of tri- 
als. This review will focus on the establishment of 
outcome measures for the management of epilepsy 
through an assessment of: (1) the characteristics of 
epilepsy, (2) the theory and measurement of outcome 
and (3) outcome standards in research and practice in 
people with a learning disability. 
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Table 1: Factors influencing outcoma-individual characteristics. 
Characteristic Factors 
Aetiology Genetics, perinatal history 
Epilepsy syndrome Difficult to treat seizures such as atonic in Lennox-Gastaut syndrome 
Abilities Association with low IQ and seizure treatability 
Personal attributes Important personality traits, e.g. behaviour 
Personal outcome wishes 
Other impairments Sensory impairments 
Cerebral palsy 
Psychiatric disturbance 
Concurrent medication Antipsychotics 
Antidepressants 
Multiole anticonvulsants 
CHARACTERISTICS OF EPILEPSY IN THE 
LEARNING-DISABLED POPULATION 
People with a learning disability are defined by in- 
telligence quotient (IQ < 70), reduced adaptive skills 
and age of onset in the developmental period, before 
the age of 18 years (DSM IV). These broad char- 
acteristics allow for considerable variation between 
individuals, yet allow us to approach general themes 
which apply to the population as a whole. Key differ- 
ences can be seen in the epidemiology of the epilepsy, 
the seizure type, the prevalence of certain epilepsy 
syndromes and the outcome of treatment. When ad- 
dressing individuals, important interindividual varia- 
tion can be influenced by the aetiology of the con- 
dition, the degree of learning disability, the presence 
of additional impairments, medication, and environ- 
mental factors. 
Epidemiology 
As is often the case, the prevalence of a particular ill- 
ness in populations of people with learning disability 
is dependent on both the source and age of the sam- 
ple population. A survey in an institution for people 
with learning disability gave a prevalence of 32%4, 
while a large community-based questionnaire survey 
of health needs in people with a learning disabil- 
ity reported a prevalence of 22.1%, making epilepsy 
second only to psychological illness as a comorbid- 
ity5. This can be compared with an estimate of the 
prevalence of epilepsy in the general population of 
between 0.4 and 1 %6. 
Seizure type, frequency and control 
In comparison with the population of people with 
epilepsy as a whole, people with a learning disability 
who also have epilepsy exhibit different types and fre- 
quencies of seizures and have a higher frequency of 
certain epilepsy syndromes. Epidemiologically based 
data on seizure type in the adult population with a 
learning disability is somewhat hampered by defini- 
tion and sampling, though the picture described in the 
adult-outpatient survey of Tobias et al3 of a relative 
increase in unclassifiable and atonic seizures would 
seem to reflect clinical experience. As well as this 
association with ah increase in single-seizure types 
there is an increase in seizure syndromes, in partic- 
ular the Lennox-Gastaut syndrome4. Seizure control 
is difficult to achieve in this patient group. This was 
confirmed in an audit of a large epilepsy clinic in 
Glasgow3 which showed that attendees with leam- 
ing disability were significantly less likely to attain 
seizure control than their non-learning-disabled coun- 
terparts. 
Individual characteristics 
A consequence of the grouping of populations is that 
it can lead to a diminution of our recognition of 
the important influences of individual characteristics 
within the group. This is particularly important in 
people with a learning disability who are a hetero- 
geneous population. These individual features have a 
major part to play in both the seizure disorder suf- 
fered by the individual and the expected response to 
treatment. Some individual characteristics influencing 
the outcome are listed in Table 1. 
Three factors emerge as having a specific influence 
on outcome: the aetiology of the disability, the de- 
gree of learning disability and the presence of other 
impairments. 
Aetiologic factors 
The underlying cause of the learning disability may 
have an impact on seizure type and outcome. The 
Common outcome measures 
Proposed Intervention 
I 
I I 
Define environment Define individual 
Describe living and care setting Aetiology 
Set outcomes with family Epilepsy syndrome, other impairments, abilities, 
or other carers medications and personal attributes 
Set familylcarer outcomes Set individual outcomes 
Fig. 1: Standard data set for the assessment of epilepsy and its treatment in an individual with learning disability. 
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seizure disorder associated with some conditions, for 
example tuberous sclerosis7, has been well defined. 
In the case of tuberous sclerosis the value of a good 
epidemiological survey was shown as this indicated a 
lower-than-expected prevalence of learning disability 
in the condition than previously recognized. The na- 
ture of epilepsy in Down’s syndrome has been well 
characterized’ where seizure disorder is often asso- 
ciated with Alzheimer’s disease, particularly if on- 
set occurs at over 30 years of age. This obviously 
has a significant impact on the outcome of new-onset 
epilepsy. 
For some other conditions associated with disabil- 
ity, such as the Fragile X syndrome, epilepsy condi- 
tions specific to the syndromes have been suggested. 
There are reports that a specific EEG abnormality 
similar to benign childhood epilepsy with centro- 
temporal spikes is present’. In this case there remains 
controversy over the validity of the finding-possibly 
due to sampling and other methodological issues”. 
In a large epidemiological survey of childhood 
epilepsy and learning disability, Steffenberg and col- 
leagues’ were able to ascertain the relative impor- 
tance of pre- and perinatal influences on an individual 
developing seizures. The study showed a higher risk 
of seizure disorder for individuals with a perinatal 
cause of their learning disability as compared with 
chromosomal abnormalities. 
Degree of learning disability 
The close association between the severity of leam- 
ing disability and the severity of the seizure disorder 
is a truism of epilepsy care. The published evidence 
supports this view. Epidemiological evidence from 
the Camberwell studies of Corbett” showed an in- 
creasing prevalence of epilepsy with decreasing in- 
tellectual functioning; a lifetime prevalence of 30% 
in children with IQ < 50 and of 50% with IQ < 20. 
The study by Steffenberg et al ” showed a prevalence 
of active epilepsy in 6-13-year-olds of 0.7%0 for mild 
learning disability and 1.3%0 for severe learning dis- 
ability. 
Ofher impairments and medication 
The association between the likelihood of having 
epilepsy if an individual has an additional impair- 
ment is strong. Hauser l3 showed an increased risk of 
epilepsy from 11 to 48% when a child with leam- 
ing disability also had cerebral palsy; an association 
confirmed by others . l4 Steffenburg and colleagues” 
showed a prevalence of cerebral palsy of 14 and 59%, 
respectively, in the mild and severe groups of pa- 
tients with learning disability and epilepsy. The se- 
vere group had a greatly increased risk of additional 
visual impairment of 3% in the mild and 37% in the 
severe population of people with learning disability 
who had epilepsy. 
Major co-morbidities such as psychiatric and or 
severe behavioural conditions should be recognized, 
with an estimated community prevalence of 32.2%‘. 
The interaction between behaviour and epilepsy is 
complex, and leads to two main confounders; first, 
the ability to confuse behaviours not associated with 
epilepsy as epilepsy-related and, secondly, the ef- 
fect of prescription of antipsychotic medication, due 
to their known epileptogenic potential. Many studies 
have looked at the prevalence of antipsychotic medi- 
cation in populations of people with learning disabil- 
ity15. Prevalence figures range from 40.2% in hospi- 
tals to 19.3% in the community and 10.1% in family 
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homes. 
Finally, the issue of polypharmacy with antiepilep- 
tic medication may also influence outcome. While 
in the general population there remains a view that 
monotherapy is the gold standard for epilepsy treat- 
ment, the complexity of epilepsy in people with a 
learning disability may have led to the high preva- 
lence of polytherapy in this population with estimates 
of 33% of patients on two anticonvulsants and 4% on 
three16. True clinical effectiveness data does not exist 
to clarify the true effect of polytherapy on outcome 
in this population. 
Environmental influences 
The context of care of people with a learning dis- 
ability is varied. While most countries are moving at 
differing rates toward a community-care-based ser- 
vice, an individual’s residence may range from a 20- 
bedded hospital ward to an individual flat in the com- 
munity. His or her carers could be elderly parents or 
constantly changing paid carers. These variations in 
environmental contexts are known to influence many 
aspects of the lives of people with learning disabil- 
ity such as the expression of behavioural disturbance, 
the amount of social integration and other activities17. 
Other key environmental factors will be the health of 
the carers and the quality of the carer-patient inter- 
action. 
THE THEORY AND MEASUREMENT OF 
OUTCOME IN PEOPLE WITH A LEARNING 
DISABILITY 
Much work has been performed in the population of 
people with learning disability as a whole in an at- 
tempt to produce a unified concept of outcome. Cen- 
tral to this has been the concept of quality of life, from 
which obvious parallels may be drawn to themes in 
epilepsy research. As in the general epilepsy field, 
quality of life remains an elusive concept in dis- 
ability, with many conceptual levels covering factors 
such as objective life conditions, subjective feelings 
of well-being and personal values. The work of Felce 
and Perry ‘* has attempted to place a cohesive struc- 
ture and develop a standardized approach to the is- 
sue. They have suggested that quality of life may be 
considered in terms of effects on a range of areas, 
such as physical well-being, material well-being, so- 
cial well-being, development, activity and emotional 
well-being. 
Of particular importance is the impact of epilepsy 
on the family. Unfortunately we know little about the 
precise impact of epilepsy on families of individuals 
who have epilepsy and learning disability. However, 
there exist important pointers from workers who have 
looked at the impact of caring individuals with dis- 
ability. The work of Todd and Sheam” has given 
pointers. They recount through interviews with par- 
ents of 33 co-resident individuals with disability that 
time, socialization and services which did not reflect 
their needs were of particular importance. 
As in generic- quality-of-life measures the usual 
methodology has remained questionnaire based. 
Questionnaire methodology is clearly hampered by 
the individuals communication difficulties and is 
therefore usually directed to carers. Unfortunately no 
reliable global measure of quality of life has been es- 
tablished. Good measures do exist to measure some 
co-morbidities in particular traits such as behaviour 
disturbance*. Other methodologies have been applied 
to assess the outcome of interventions in people with 
a learning disability. Probably the most sensitive and 
responsive to the assessment of an individual’s ac- 
tivity in his/her ordinary setting has been the appli- 
cation of computerized direct observation methodol- 
ogy. 
Direct observation of patients through computer 
and video monitoring also has potential in measur- 
ing outcomes in patients with learning disability and 
epilepsy. Unlike informant-based ratings which are 
notoriously unreliable, this technique has the ad- 
vantage of allowing for objective and reliable mea- 
surement of behaviour. It also allows the direct as- 
sessment of environmental effects on behaviour and, 
through the use of video recordings, often detects be- 
haviours that go unnoticed by carers. Data may be 
directly entered onto a computer, making the analysis 
of behaviour much quicker, simpler, and less suscep- 
tible to bias. 
As with most systems, there are a few disadvan- 
tages. These include obtaining only snapshots of be- 
haviour, the process may be time consuming, people 
must be trained to use the equipment, and data relia- 
bility must be continually checked. 
This approach to patient assessment appears, there- 
fore, to provide good direct information on patient 
behaviour in the home, and has the added advantage 
of removing biases which can so often influence re- 
porting by parents and carers. 
The application of direct observation has generally 
been in the context of assessing an individual’s inter- 
actions and activities in various community or hospi- 
tal settingst7**0 
Generic outcome measures 
The validity of generic epilepsy outcome measures 
has been reviewed elsewhere*. In summary, outcomes 
Common outcome measures 
for epilepsy interventions may be divided into three 
broad areas. First, there is the seizure-related out- 
come which is dependent on seizure count; this usu- 
ally subdivides into ‘seizure free’ or ‘> 50% reduc- 
tion in seizure count’. Secondly, side-effect related, 
which is usually assessed by either (i) reported ad- 
verse effects or (ii) drop out from a trial. It should 
be noted, however, that while the latter approach (i.e. 
recording drop out rate) is considered to measure the 
acceptability of a treatment, it may of course reflect 
lack of efficacy. Thirdly, quality-of-life related; an in- 
creasingly large body of literature exists in this area*‘. 
These measures are usually patient-experience based 
though they may also include other family members 
or health professionals. 
OUTCOME STANDARDS IN RESEARCH AND 
PRACTICE 
Drawing together the themes we have discussed so 
far there remain two questions, namely: What should 
we measure? and How should we measure it? 
In this section we will focus on the key components 
to methodology. The precise measurement scales used 
will be discussed elsewhere’. The.first step in actively 
implementing a standard methodology involves defin- 
ing the individual patient. This may be approached by 
assessment of several variables, including ability, per- 
sonal attributes, aetiology and seizure syndrome. It is 
recommended that standard data sets are used to de- 
scribe aetiology and seizure type. Validity of diagno- 
sis and comparability between groups will be greatly 
helped by this. 
The second step involves the use of measures, 
which are sensitive to change, used to determine the 
efficacy of a treatment in a specific patient. In both 
research and practice the measurement of an appro- 
priate baseline is essential. Appropriate measures in- 
clude seizure frequency (which may be recorded on a 
seizure chart), behaviour (monitored by a scale such 
as the Aberrant Behaviour Checklist), social interac- 
tion, patient independence, contact and participation 
(assessed by direct observation), and general well- 
being (monitored on a global scale involving the tar- 
geting of certain baselines such as sleep or appetite, 
or a parent OF carer’s view of how the patient is and 
whether a certain variable has changed over time). 
The third area is the measurement of the effect of 
the patient’s epilepsy on the carers. It is hard to give 
precise guidance here. It is an important issue and the 
development of scales based on carers experiences 
will be useful. In the absence of validated epilepsy- 
related scales, generic quality-of-life measures such 
as the SF36 could be used or specific-trait measures 
such as the Beck depression inventory, though we 
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must be careful that we do not inappropriately apply 
pathology to the role of the carer. 
Figure one illustrates how such measures may be 
applied in either research or clinical settings. 
CONCLUSION 
Currently available measures to assess the outcomes 
of therapeutic interventions on epilepsy in people 
with learning disability are often inappropriate and/or 
have not been validated in this patient group. In order 
to adequately assess the impact of therapeutic inter- 
vention in these patients we have suggested a stan- 
dard methodology and outcome measures that may 
be used to improve management. The outcome mea- 
sures should be sensitive to change, include informa- 
tion on individual characteristics and allow for vari- 
ables such as treatment compliance and environmen- 
tal confounders. In addition, new technologies, such 
as direct observation (through computer systems and 
video recordings) appear to have much potential and 
should be considered as effective tools in minimizing 
bias and providing direct, quick and ‘reliable assess- 
ment of behaviour. 
Of course these suggestions may not be fully inclu- 
sive and other outcome measures, which may include 
a reduction in polypharmacy, reduced hospital care, 
improved carer education and client satisfaction, may 
be considered. In addition to implementation of the 
above tools, delivery of these outcome measures may 
be achieved through a number of initiatives, including 
clinical audits, training programmes’ on epilepsy and 
polypharmacy, specific clinics, patient surveys, ad- 
ministrative support, and care-group task forces and 
business plans which enlist the support of a range 
of professionals in the field (e.g. Chief Executives, 
Clinical Directors, Business Managers, Psychiatrists, 
Clinical Nurse Specialists, General Practitioners). 
While several needs remain to be met (for example, 
developing a sufficiently sensitive assessment scale) 
we believe that outcome monitoring may be signifi- 
cantly improved in this the most challenging of pa- 
tient groups, by actively implementing at least some 
of the measures described above. 
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